



1

Supplementary Figure 1










Supplementary Figure 1. Comparison of VIII (Merck) vs VIII-GMP (Ardena) and titration of VIII-GMP.

(A) Total T-cell fold expansion by the end of manufacture at Day 8 (B) % Tcm subset in CAR CD8s at Day 8, determine by flowcytometry as (CD62L+/CD45RA-) and (CCR7+/CD46RA-). (C) Extended phenotyping depicting % CD27+/CD28+ cells characterised by flowcytometry. Representation flowcytometry plots from one donor in the UT and 1 μ M VIII-GMP are depicted to the right. (D) CD4/CD8 CAR fold expansion following a 7-day co-culture with irradiated RAJI-19WT

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

target cell lines. (E) Graphs depicting % killing of RAJI-19GFP target cells post rechallenge of NT or CAR T-cells in a 72-hour killing assay. Results from all conditions were normalised to the untreated non-transduced (NT) condition at each E:T ratio. All data sets compare 1 μ M VIII-Merck and 1 μ M VIII-GMP. VIII GMP is further titrated to 2.5 μ M and 5 μ M at n=2 per condition ± SD and/or individual data points.





Supplementary Figure 2. Summary of CAR-T phenotype throughout manufacture.

Graphical representation of Tn (CCR7+/CD45RA+), Tcm (CCR7+/CD45RA-), Te (CCR7-/CD45RA-) and Tte (CCR7-/CD45RA+) subsets in total CAR T-cells determined by flowcytometry, \pm SD at baseline and throughout manufacture. Statistical comparisons were made against paired UT sample in each subset at matched timepoints, n=6. Two tailed Mann-Whitney U test, ns P>0.05, *P<0.05 and ** P<0.01.

Method: Systemic leukaemia was established via intravenous injection of 5×10^5 NALM6-FLUC followed by 5×10^5 non-transduced (NT) or CAR T-cells 4 days later. Tumour burden was measured bi-weekly via bioluminescent imaging (BLI) using the IVIS spectrum in-vivo imaging system (Perkin Elmer) following intraperitoneal (IP) injection of 2mg D-luciferin in 200µl PBS. Photon emission from NALM6 cells was measured as photons/sec/cm2/steradian. Mice were humanely euthanised Day 21 and spleen/bone marrow samples were harvested in cold Hanks Balanced Salt Solution (HBSS) (Sigma Aldrich) for downstream analysis. Spleens were gently pressed over a 70µm and subsequently a 30µm cell strainer to dissociate. Bone marrow was flushed with PBS from femoral shafts over a 70µm and subsequently a 30µm cell strainer. CountBrightTM beads were added to samples to determine absolute cell numbers, and flowcytometry was performed on the BD LSRFortessaTM and analysed using FlowJo v10 software.


Supplementary Figure 3






Е

BM Total CAR+




Supplementary Figure 3. In-vivo model and CAR T-cell analysis from mouse spleen and bone marrow at Day 21.

(A) Tumour burden measured by bioluminescent imagining (BLI) in NALM6 tumour established mice treated with non-transduced (NT) T-cells or CAR T-cells manufactured with (VIII) or without (UT) \pm SEM (B) Residual percentages of total T-cell and tumour cells in mouse spleen and bone marrow at Day 21, depicting individual data points (C) Percentage of CAR+ CD4/8 in spleen and bone marrow at Day 21 in NALM6 tumour established mice treated with UT/VIII CAR T-cells, depicting individual data points. (D) Frequencies of CCR7+/CD27+ in total CAR T-cells and CD27+/CD28+ in CD8 CAR T-cells in bone marrow of mice treated with UT/VIII CAR T-cells, depicting individual data points. (E) Graphical representation of Tn (CCR7+/CD45RA+), Tcm (CCR7+/CD45RA-), Te (CCR7-/CD45RA-) and Tte (CCR7-/CD45RA+) subsets in total CAR T-cells from bone marrow determined by flowcytometry, \pm SD. (A-E) Cells derived from one healthy donor, n=4 mice per group. (A) Two-way ANNOVA corrected for multiple comparisons by Tukey's test on log transformed data, ns P>0.05 and ** P<0.01. (B-C) Two-way ANNOVA corrected for multiple comparisons by Bonferroni's test, ns P>0.05. (D-E) Two tailed Mann-Whitney U test, ns P>0.05.




CAR CD8+ PAT PCA



Supplementary Figure 4. PAT PCA of polyfunctional profiles.


Polyfunctionality Activity Topography (PAT), Principal Component Analysis (PCA) of CD4 and CD8 T-cell subsets demonstrating primary polyfunctional profiles where radius is proportional to secretion frequency. Determined using IsoplexisTM platform, following 20-hour 2:1 RAJI-19WT:CAR stimulation, n=4.



Supplementary Figure 5. CAR T-cell transcriptome signature


(A-B) Heat map representation of transcripts specific to cell activation, FOXO1 and effector function in CD8 CAR T-cells and FOXO1/co-stimulatory transcripts in CD4 CAR T-cells. Colour represents low to high transcript expression. Rows are specific to each gene and columns highlights expression in each donor following UT/VIII manufacture. Only significantly differentially expressed pathways and genes are included in figures at a p<0.05 cut off.





Supplementary Figure 6. Phenotype analysis of baseline T-cells derived from healthy donor and B-ALL patients.

(A) Graphical representation of Tn (CCR7+/CD45RA+), Tcm (CCR7+/CD45RA-), Te (CCR7-/CD45RA-) and Tte (CCR7-/CD45RA+) subsets in total T-cells from healthy donor (HD) and B-ALL patients at baseline determined by flowcytometry, \pm SD. (B) Percentage CD27+/CD28+ in total T-cells from healthy donor (HD) and B-ALL patients at baseline, depicting individual data points. Black squares in patient group represent patients in remission and red squares represent patients with CD19+ relapse. (A-B) n=6, Two tailed Mann-Whitney U test, ns P>0.05 and ** P<0.01.



Supplementary Figure 7. Intracellular cytokine production

(A) Pie chart of proportion of intracellular cytokines measured by flowcytometry following RAJI-19WT stimulation in B-ALL patient CAR-T manufactured at small-scale. Arcs represent proportion of single or polyfunctional secretion. (B) Percentage of total CAR-T producing GZMB in healthy donor (HD) or B-ALL patient in small-scale assessments at the end of manufacture or at rechallenge using CAR-T co-cultured with RAJI-19WT targets 7-days prior, \pm SD. (C) Pie chart of proportion of intracellular cytokines measured by flowcytometry following RAJI-19WT stimulation in B-ALL patient CAR-T manufactured at Prodigy scale. Arcs represent proportion of single or polyfunctional secretion. (D) Percentage of total CAR-T producing GZMB in B-ALL patient Prodigy-scale assessments at the end of manufacture or at rechallenge using CAR-T co-cultured with RAJI-19WT targets 7-days prior, \pm SD. (A-B) n=6. (C) n=3 (B) Two tailed Mann-Whitney U test, ns P>0.05. *P<0.05 and ** P<0.01. (D) n=3, Two tailed Mann-Whitney U test, ns P>0.05.